Obesity, a persistent imbalance of calories, has become one of the major clinical factors that result in many metabolic disorders. Despite excellent anti-obesity properties, the poor aqueous solubility of hesperidin (HES), a flavonoid, hampers its applicability. To resolve this issue and conquer oral administration's drawbacks, our study has concentrated on encapsulating HES in nanostructured lipid carriers (NLCs) and incorporating the NLCs into microneedles (MNs). By developing HES-loaded NLCs (HES-NLCs) with hyaluronic acid (HA) as a base design to form a microneedle patch (HES-NLCMNP), the study aimed to increase the stability and bioavailability of HES and provide an innovative way for the management of obesity. HES-NLCs were loaded to the microneedle, to promote anti-obesity activity. The microneedle tip, which has been composed of HA, will act as a biodegradable polymer that could effectively deliver the activity of HES-NLC to the blood stream. Furthermore, the base of the microneedle patch composed of polyvinyl alcohol (PVA) offered excellent flexibility, releasing HES and providing resistance to any adverse effects. Analysis revealed that the prepared HES-NLCs have desirable physical characteristics with an extended-release profile. The optimised NLC formulation (F